Management of Itch in the Elderly: A Review.

Introduction

Diseases that cause itch are some of the most common dermatologic complaints in the elderly (age 65 and above) with prevalence estimates up to 37.5% [ 1 – 3 ]. Chronic itch, defined as present for more than 6 weeks, can be debilitating and significantly affect quality of life [ 4 – 7 ]. Primary dermatologic conditions account for up to 28% of the chronic itch seen in some elderly populations [ 8 ]. In addition, the elderly are more likely to have itch due to age-related changes in the skin, co-morbid systemic disease, medication effects, and psychological conditions [ 9 ]. Medical workup for an elderly patient with chronic itch requires special attention to the patient’s history of disease, consideration of undiagnosed systemic disease, co-morbid psychologic conditions, as well as comprehensive review of the patient’s current topical and systemic therapies. The clinical presentation of itch may vary widely depending on the underlying etiology. Primary dermatologic conditions will most often have a recognizable skin manifestation ranging from a localized rash to erythroderma, while neuropathic, systemic, or psychogenic etiologies may present with no rash or only secondary skin lesions. Despite a thorough medical review and workup, chronic itch has no identifiable cause in up to 11% of cases [ 10 ]. Chronic pruritus of unknown origin is common in the elderly and most cases likely represent the same unknown etiology as the general population [ 11 ]. In the elderly, management of chronic itch may be complicated by a variety of issues, including differential effects of medications in the elderly, co-morbid health conditions, cognitive disorders, physical limitations, and polypharmacy. This article aims to provide an updated review of causes of chronic itch in the elderly and management strategies in this population. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Age-Related Changes in the Skin

The most common cause of chronic itch in the elderly is xerosis related to aging, seen in over 50% of the elderly [ 12 ]. The underlying mechanism is thought to be due to loss of integrity of barrier function provided by the stratum corneum and subsequent inability to maintain epidermal water content. With age, alkalization of the skin leads to dysfunction of enzymes required for basic repair functions and production of lipids that are necessary for maintenance of the water barrier. Alkalization has also been shown to lead to increased activity of serine proteases and activation of protease-activated receptors (PARs) that induce non-histaminergic chronic itch [ 13 , 14 ]. Aging skin has been shown to have reduced levels of ceramide-generating enzymes within the stratum corneum [ 15 ]. Also, aged skin shows reduced sebum production and in female patients this occurs with the onset of menopause, implying a role of estrogen reduction [ 16 ]. Expression of aquaporins that are integral in the maintenance of epidermal water content has been shown to be reduced in aging skin [ 17 ]. Xerosis typically presents as itch with dry, cracked, flaking skin often on the extremities and trunk. The scratching response leads to further disruption of the barrier contributing to risk for superimposed infection and continuation of the itch–scratch cycle can lead to further inflammation and worsening of chronic itch.

Immune function is expected to decline with age, with decreases in the response of the innate and adaptive immune systems. There is a reduction of naïve T cells, favoring memory cells as well as a shift toward CD8 + predominance over CD4 + and a predominance of the Th2-type response over the Th1-type response, with corresponding inflammatory cytokines [ 18 – 20 ]. B cell populations are also reduced in number accompanied by imbalance of immunoglobulin production [ 21 ]. These and other adaptive immunologic changes lead to a diminished response against novel pathogens, malignancy, and vaccinations seen in the elderly [ 22 ]. Reduced barrier function contributes to increased susceptibility to pathogens as well as release of proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor alpha, predisposing to inflammatory skin conditions [ 20 , 23 ]. In addition, morphologic changes and reduction in number of Langerhans cells have been demonstrated in aging and photodamaged skin [ 24 , 25 ].

Finally, degenerative diseases that more commonly affect the elderly may cause central or peripheral nerve damage leading to neuropathy and neuropathic itch (NI). NI can present a diagnostic challenge, since secondary excoriations may mimic a primary dermatologic condition. Characteristic features include absence of primary dermatologic lesions, non-responsiveness to antihistamine, relief from application of cold compress, and is more likely to be accompanied by depressed mood, sleep disturbance, and reduction in quality of life [ 7 ]. Also, NI tends to be rated by the patient as severe in quality [ 10 ]. Another hypothesis to explain NI is evidence of reduced epidermal nerve fiber density in the elderly, potentially leading to reduced density of nerves that inhibit the itch sensation [ 26 ]. Intraepidermal nerve fiber density has been shown to be reduced in those with chronic itch, with increased sensitivity to pruritic stimulation [ 27 ].

Dermatologic Conditions Causing Itch in the Elderly

Seborrheic Dermatitis

Common in the elderly, seborrheic dermatitis is associated with Malassezia yeast species in the setting of reduced immune function. This disease in the elderly has also been shown to have an association with Parkinson disease and psychiatric conditions such as depression and anxiety [ 28 , 29 ].

Stasis Dermatitis

Chronic venous insufficiency leading to stasis dermatitis is a pruritic disease seen in increased prevalence in the elderly [ 2 , 8 ]. The common manifestations of edema, brownish plaque with scale, petechiae, and pruritus are most typically seen in the lower leg above the medial malleolus.

Nummular Eczema

Considered a variant of atopic dermatitis (AD), nummular eczema can present as an acute or chronic pruritic eruption in the elderly even in the absence of prior atopic disease [ 2 , 30 ]. Age-related xerosis is likely a predisposing factor [ 31 ].

Contact Dermatitis

Whether of the allergic or irritant form, contact dermatitis is common in the elderly occurring in up to 13% [ 8 ]. Reductions in epidermal barrier and immune function are likely predisposing factors in the elderly but may also contribute to a more subtle inflammatory response [ 32 ].

Prurigo Nodularis (PN)

PN is a condition commonly seen in elderly individuals in the setting of chronic itch and scratching caused by any number of primary dermatologic, neuropathic, and systemic diseases such as end-stage renal disease (ESRD) and human immunodeficiency virus. PN nodules and lichenified lesions are usually distributed in “reachable” areas on the extremities, upper back, and buttocks. PN-related itch may disrupt sleep, affect quality of life, and is associated with psychiatric co-morbidities [ 33 ].

Psoriasis

Itch associated with psoriasis is a commonly encountered symptom in the elderly [ 8 , 34 ]. In the elderly, psoriasis typically presents as chronic plaque-type similar to the general population; however, later onset psoriasis may present with a less severe presentation [ 35 ].

Bullous Pemphigoid (BP)

BP is most often seen in the elderly and known triggers include viral infections and certain medications but the majority of cases have no apparent trigger [ 36 ]. BP is also associated with Parkinson disease and dementia [ 37 ]. Itch in BP has been recently correlated to several mediators including substance P and IL-31 and activation of eosinophils and basophils [ 38 ]. BP may initially present with a prodrome of non-bullous, non-specific eczematous skin changes accompanied by pruritus lasting months to years prior to the presentation of tense bullae [ 39 ].

Scabies

Scabies is commonly diagnosed at the extremes of ages with outbreaks notable among those living in care facilities or nursing homes [ 40 ]. Itch caused by scabies is thought to be mediated by non-histaminergic pathways involving tryptase and its corresponding receptor protease-activated receptor 2 (PAR2) as well as transient receptor potential vanilloid receptor 1 and transient receptor A1 (TRPV1 and TRPA1) [ 41 ]. Scabies presents as an intensely pruritic rash typically with excoriations evident. Pruritus is often most intense during the nighttime hours or after hot showers. Scratch-induced skin damage may lead to secondary infection with staphylococcal or streptococcus species, particularly in those with suppressed immune conditions or co-morbid disease states. The mite has a predilection for the acral sites but whole body involvement is a common feature of disease in the elderly or immunocompromised.

Neuropathic Itch

Diabetes Mellitus (DM)-Related Polyneuropathy

Itch is reported in up to 26.3% of individuals with DM [ 42 ]. Pruritus is more likely to occur in individuals with typical symptoms of lower extremity polyneuropathy but may also present as generalized itch or localized to areas other than the lower extremities such as the scalp, trunk, or genitals [ 43 ].

Post Herpetic Itch

Post herpetic neuralgia (PHN) is a sensory syndrome secondary to herpes zoster reactivation (shingles), which most commonly affects the elderly because of age-related reduction in immunologic suppression of the virus. Viral reactivation may damage sensory afferents in the affected dermatome, causing pain, itch, and paresthesia that may last months or years following the resolution of skin lesions. The likelihood of an individual suffering from PHN increases with the age at which they are affected, with an incidence of 10% in those affected at ages 60–69 and up to 20% in those over age 80 [ 44 ].

Radiculopathy

Nerve compression due to spinal osteoarthritis, infection, trauma, or tumors may lead to NI. Notalgia paresthetica (NP) and brachioradial pruritus (BRP) are two well-described nerve compression syndromes causing itch in the elderly, more commonly in women. NP is often related to osteoarthritic degeneration and impingement of thoracic nerve roots leading to pruritus accompanied by burning or pain in the upper back. Often, secondary skin changes are notable as a hyperpigmented patch. BRP is related to compression pathologies in the C3–C7 region [ 45 , 46 ]. The itch, stinging, and burning of BRP is often bilateral and typically localized to the dorsolateral forearms and arms, at times extending to the shoulders and in some cases progressing to generalized pruritus involving the lower extremities and trunk [ 47 ].

Systemic or Organ-Specific Disease

Diseases of the hepatobiliary, hematologic, and renal systems are well-known causes of chronic itch. As a result of the increased prevalence of such diseases in the elderly, comprehensive workup of all major organ systems including complete blood count, erythrocyte sedimentation rate as well as renal, hepatobiliary, and thyroid function studies is necessary, particularly in the absence of evidence of a primary dermatologic or neurogenic etiology. Determining the cause of itch related to a systemic disorder is crucial, as it may be the presenting symptom of a progressive disease for which treatment is indicated.

ESRD-Related Itch (Uremic Itch)

ESRD-related itch is reported in up to 66% of those undergoing hemodialysis and typically involves the torso and is symmetrical in the extremities [ 48 , 49 ]. The cause of itch in those with ESRD is not fully understood but the mechanism has been proposed to be due to several factors including lowered threshold for itch, hyperparathyroidism, and imbalance of endogenous opioids [ 50 ].

Cholestatic Itch

The primary feature of hepatobiliary cholestatic itch is itch on the palms and soles [ 50 , 51 ]. The pathophysiology of cholestatic itch has not been wholly elucidated, but serum levels of lysophosphatidic acid and autotaxin, endogenous opioids, histamine, and bile acids have been shown to be elevated in those affected with cholestatic itch, alluding to their involvement in itch pathogenesis or at least correlation with causative factors [ 52 ].

Myeloproliferative Disorders and Malignancy

Polycythemia vera (PV), essential thrombocytosis, and primary myelofibrosis are known to have aquagenic itch as a predominant symptom and it is the presenting symptom in up to 36% of cases of PV [ 53 , 54 ]. The relationship is thought to be related to proliferation of mast cells and/or basophils [ 55 ]. Pruritus is a well-described symptom associated with hematologic malignancies, reported in up to 30% of patients with Hodgkin lymphoma and multiple myeloma, and less frequently in non-Hodgkin lymphoma and leukemia [ 56 , 57 ]. Generalized itch with or without eczematous lesions precedes the diagnosis of Hodgkin lymphoma in some cases [ 58 ]. Malignancies originating in the skin itself may also present with itch. Cutaneous T cell lymphoma (CTCL) commonly manifests as itch and itch severity has been found to correlate with severity of disease [ 59 ]. Non-melanoma skin cancers, basal cell and squamous cell, present as localized itch in 33% and 43% of cases, respectively [ 60 ]. Internal malignancies such as pancreatic or biliary tumors may lead to cholestatic itch [ 61 ]. Itch may present as a paraneoplastic sign of hematologic malignancies or solid tumors without associated dermatologic lesions or along with acanthosis nigricans, dermatomyositis, transient acantholytic dermatosis (Grover’s disease), or eruptive seborrheic keratosis (Leser–Trélat sign) [ 57 ].

Psychogenic Itch

Psychiatric disorders are common in the elderly but may be under-recognized or under-reported as a result of cognitive co-morbidities in this population [ 62 ]. Psychogenic itch refers to an intense urge to scratch or pick at the skin, without known primary dermatologic or systemic etiology. Thus, psychogenic itch is often a diagnosis of exclusion and it is not recognized in the current Diagnostic and Statistical Manual of Mental Disorders (DSM-V). Psychogenic itch most commonly presents in individuals with psychiatric conditions and has been associated with obsessive compulsive disorder, somatic symptom disorder, excoriation disorder, fibromyalgia, and delusional infestation [ 63 ]. Psychogenic itch has also been reported as a symptom of neurodegenerative disorders such as dementia and as an effect of medications activating dopaminergic pathways [ 64 , 65 ].

Medication-Induced Itch

A number of medications commonly prescribed in the elderly induce itch as a known adverse effect, most commonly opioid pain medications, antihypertensives (angiotensin-converting enzyme inhibitors, calcium channel blockers), antibiotics (penicillin derivatives), and antidepressants (tricyclic antidepressants, TCAs) [ 66 , 67 ]. Pruritus is reported in 2–10% of patients treated with oral systemic opioids, but that percentage increases dramatically with epidural or intrathecal administration [ 68 ]. Opioid-induced itch is thought to be due to activation of centrally located mu-opioid receptors as well as peripheral mast cell activation and subsequent histamine action [ 68 ]. The new anticancer checkpoint inhibitors, specifically ipilimumab (targeting cytotoxic T lymphocyte associated antigen 4, CTLA4) and pembrolizumab (targeting programmed cell death protein 1, PD-1) for use in the treatment of melanoma have been shown to induce pruritus with and without rash [ 69 ]. Targeted inhibitors of epidermal growth factor receptor (EGFR), indicated for use in metastatic colon cancer, head and neck cancer, and lung cancer, as well as BRAF inhibitors used for metastatic melanoma have notable dermatologic side effects including pruritus in up to 31% and 18% of patients, respectively [ 70 ].

Topical Treatments and Considerations in the Elderly

Treatment of xerosis is targeted at improving the barrier function of the skin and limiting epidermal water loss. Initial treatment measures may be non-pharmacologic in nature, including alterations to the bathing regimen (mild low pH cleansers, lukewarm water), frequent moisturization with ointments or cream on damp skin, and avoidance of irritants (Table 1 ). Daily oatmeal baths are another treatment option as moisturization with colloid oatmeal-based products has been shown to improve appearance of lesions and reducing pruritus in patients with xerosis and other skin conditions [ 71 , 72 ]. Topical urea, a moisturizing keratolytic agent, is an effective treatment for several causes of itch including xerosis, with minimal side effects [ 73 ]. In addition, a local anesthetic such as pramoxine added to emollients has been shown effective in treatment of ESRD-related itch [ 74 ]. Table 1 Treatment of itch by type in the elderly Pruritus etiology Treatment suggestions in the elderly Age-related xerosis Mild, low pH cleansers, frequent moisturization, oatmeal baths Topical urea Topical emollients with pramoxine Primary dermatologic conditions Topical calcineurin inhibitors for AD, NE, SD, PS, CD Topical phosphodiesterase 4 inhibitors for AD and hand dermatitis Methotrexate for AD, PS, BP Biologic therapies (i.e., dupilumab) for AD with consideration of immunologic adverse effects of some (i.e., JAK inhibitors for PS) Phototherapy with consideration of photosensitive medications Use with caution : Topical corticosteroids avoided or used for limited term only Systemic corticosteroids, considering diabetes, gastrointestinal risks, and reactions with NSAIDs First-generation antihistamines and other strongly anticholinergic medications Neuropathic itch Local anesthetics (pramoxine or lidocaine) Topical capsaicin Topical ketamine–amitriptyline–lidocaine Oral low-dose gabapentinoids with dosage adjustment for renal disease and adverse effects Systemic disease Topical emollients with pramoxine for uremic itch Topical capsaicin for uremic itch Oral low-dose gabapentinoids with dosage adjustment for renal disease and adverse effects Oral kappa-opioid agonists and mu-opioid antagonists for uremic and cholestatic itch Oral mirtazapine Oral NK1 inhibitors (i.e., aprepitant) for malignancy and uremic itch Phototherapy with consideration of photosensitive medications Psychogenic itch Consider SSRI or SNRI in those without history of falls or fractures Use with caution : TCAs and other highly anticholinergic agents AD atopic dermatitis, NE nummular eczema, SD seborrheic dermatitis, PS psoriasis, CD contact dermatitis, BP bullous pemphigoid, JAK janus kinase, NSAID non-steroidal anti-inflammatory, NK1 neurokinin 1, SSRI selective serotonin reuptake inhibitor, SNRI serotonin and norepinephrine reuptake inhibitor, TCA tricyclic antidepressants

Treatment of NI is often challenging, as it is typically resistant to antihistamines and topical corticosteroids [ 75 ]. An effective topical treatment is capsaicin 0.025–0.075%, which acts through activating the TRPV1 receptors in the skin to desensitize local nerves [ 76 ]. A significantly higher capsaicin concentration of 8% in patch form has shown to be effective in treatment of NI [ 77 – 79 ]. However, the high cost of this drug has prevented its use in the USA. The effect of capsaicin is induction of localized pain and burning sensation that can be reduced by application of local anesthetic cream. Another topical treatment that has demonstrated effectiveness in NI is a combination of ketamine–amitriptyline–lidocaine [ 80 , 81 ]. The mechanism of this topical is through blockade of the N -methyl- d -aspartate receptor and sodium channels, which is proposed to reduce sensitivity of local peripheral nerves [ 80 ].

Topical corticosteroids are among the first-line treatments for common itch pathologies in which there is an inflammatory component such as AD, psoriasis, seborrheic dermatitis, or contact dermatitis [ 82 , 83 ]. Long-term use of topical corticosteroids can cause thinning, atrophic effects, and disruption of skin barrier function, which may exacerbate atrophic changes already present in aging skin [ 84 ]. Therefore, long-term use of topical corticosteroids should be avoided if possible. Other topical agents such as calcineurin inhibitors do not have known atrophic effects on the skin and may be a reasonable alternative for treatment of these inflammatory conditions [ 85 , 86 ]. Another alternative with minimal adverse effects is crisaborole, a phosphodiesterase 4 inhibitor that reduces pro-inflammatory cytokines and has shown effectiveness in itch in moderate to severe AD [ 87 ].

Systemic Medications and Precautions in the Elderly

Oral and systemic medications are commonly used in geriatric itch, but require cautionary use (see Tables 1 , 2 ). Adverse effects of medications are generally more common in the elderly. Polypharmacy potentiates the risk for drug–drug interactions, as there are many medications commonly used in the elderly that have specific interactions with the hepatic cytochrome p450 (CYP) metabolism pathways. Substrates of CYP enzymes likely to be affected by these metabolic effects include several commonly used medications, highlighting the necessary review of all medications, dermatologic and otherwise, prior to initiating treatment [ 88 , 89 ].

In addition to drug–drug interactions, adverse effects should be considered carefully in the elderly. Medication adverse effects such as sedation, vertigo, or fatigue that may be mild or tolerated in the younger population may exacerbate already existing limitations in mobility and cognitive function. Careful review of medication side effects is necessary as well as considerations for initiating dosages at reduced levels, particularly with medications that have a narrow therapeutic window [ 88 ].

Physiologic changes with age also contribute to the effective distribution and elimination of medications. Muscle mass is generally decreased in the elderly while body fat is increased, leading to potential prolongation of effects or severity of lipid soluble medications [ 90 ]. A large percentage of the elderly population has reduced kidney function. Dermatologic medications used for itch-related diseases that undergo renal clearance and thus require consideration of renal dosing include cetirizine and gabapentin, among others [ 88 ]. Table 2 Topical and systemic therapies for itch in the elderly Topical therapies for itch in the elderly Systemic therapies for itch in the elderly Benefits Limited systemic effects and therefore fewer interactions and potential for toxic effects Systemic effect for treatment of extensive pruritus Application as needed to target areas May target receptor, cytokine, or immune process specific to underlying disease Limitations Burdensome to use in extensive skin disease, may require large volume Potential for systemic adverse effects and medication interactions Requires patient education of application technique May require dosage adjustments for systemic disease states Topical corticosteroids may lead to atrophic changes in elderly

First-Generation Antihistamines

These drugs have been commonly used to relieve itch for decades, despite little supportive data for their effectiveness in non-histaminergic etiologies. The American Geriatric Society (AGS) Beers Criteria have made a strong recommendation against their use in the elderly as a result of their highly anticholinergic properties and risk for delirium [ 88 , 91 ]. In addition, recent evidence from a large prospective cohort study of elderly patients shows that use of medications with strong anticholinergic effects (i.e., first-generation antihistamines or TCAs) may contribute significantly to risk for Alzheimer disease [ 92 ]. Second-generation antihistamines are preferred for treatment of histaminergic forms of itch such as chronic urticaria owing to their reduced anticholinergic effects [ 93 ]. Loratadine, however, has the most anticholinergic effects of all the second-generation antihistamines, and should be avoided in the elderly [ 88 ].

Antidepressants

TCAs such as amitriptyline and doxepin are also recommended against because of their anticholinergic effects as well as orthostatic hypotension [ 91 ]. TCAs have been shown to be effective in the treatment of nocturnal itch and psychogenic itch [ 75 ]. Alternatives for the treatment include antidepressants with a more favorable side effect profile in the elderly, such as the selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) as well as behavioral therapy or psychotherapy [ 75 ]. The SSRIs paroxetine, fluvoxamine, and sertraline have been shown to have antipruritic effects in AD, lymphoma, and cholestatic pruritus [ 94 – 96 ]. However, the SSRIs and SNRIs are not without their potential adverse effects in the elderly, as both classes were recently added to the AGS Beers Criteria to be avoided in those with a history of falls or fractures, as a result of evidence increased risk of hip fractures [ 97 ]. In addition, paroxetine has the greatest anticholinergic properties of that class of medications and therefore would not be the SSRI of choice for treatment in an elderly patient [ 91 ]. Mirtazapine, an antidepressant that blocks adrenergic alpha 2 receptors and 5-HT 2 receptors has shown effectiveness at low doses in relieving nocturnal itch. This medication in low doses of 7.5–15 mg may be preferred for select patients owing to its effects on somnolence and increased appetite [ 98 ].

Systemic Corticosteroids and Immunosuppressants

Corticosteroids are used frequently in inflammatory and immune-mediated dermatologic conditions that cause itch. The known adverse effects of systemic include hypertension, hyperglycemia, osteoporosis, and myopathy. In addition, caution must be taken to avoid the use of corticosteroids in combination with the non-steroidal anti-inflammatories (NSAIDs) in the elderly, as this increases the risk of peptic ulcers and gastrointestinal bleeding [ 91 ]. Other pan-T cell immunosuppressants such as cyclosporine, which has many side effects as high blood pressure, renal damage, and systemic infections, should be avoided. Low-dose methotrexate is a safer alternative that can be effective for itch caused by AD, psoriasis, BP, and urticaria [ 99 ].

Anti-Epileptics

Gabapentinoids such as gabapentin and pregabalin show efficacy in treating NI due to PHN, BRP, and NP, or spinal cord injury as well as uremic itch [ 42 , 100 – 102 ]. Because of renal clearance, dose adjustments may be required in the elderly or those with kidney disease. Potential adverse effects such as sedation and ataxia are of concern in elderly patients with limited baseline mobility or cognitive functioning [ 101 ]. To moderate these unwanted effects, it is recommended that dosage of gabapentin in the elderly be initiated at 100–300 mg (pregabalin 25–75 mg) at night and slowly titrated up [ 88 ].

Opioid System Targets

Opioids are a well-described cause of medication-induced pruritus and do so through activation of central mu-opioid receptors [ 103 ]. Medications that antagonize the mu-opioid receptor, such as naloxone, naltrexone, or nalmefene, have been demonstrated to be effective in reducing itch in chronic urticaria, AD, PN as well as cholestatic and uremic itch [ 104 ]. Side effects including nausea, vomiting, diarrhea, dizziness, and fatigue and the potential for hepatic injury at high doses necessitate caution with the use in the elderly [ 105 ]. In contrast, activation of kappa-opioid receptors inhibits pruritus. Butorphanol, a kappa-opioid agonist with some mu-opioid antagonist properties, has been shown in case series to effectively reduce itch due to PN, cholestasis, uremic itch, and idiopathic pruritus in elderly patients [ 104 , 106 ]. Nalfurafine, which has a similar mechanism of action, has been demonstrated in randomized controlled trials (RCTs) to reduce uremic itch and cholestatic itch and is currently only used clinically in Japan [ 107 ]. Side effects have been noted to be minimal with insomnia most commonly reported followed by constipation and somnolence [ 107 ]. New kappa-opioid agonists in the pipeline such as nalbuphine and CR845 show promise in early phase trials for uremic itch with a favorable safety profile [ 106 , 108 , 109 ].

Biologic Therapies

Dupilumab, a monoclonal antibody targeting the receptor for IL-4, has been shown in large RCTs to reduce symptoms and improve quality of life in those with moderate to severe AD [ 110 , 111 ]. The average age of participants in these trials was under 50, providing little evidence of efficacy in the elder population. We have gained clinical experience using this drug in older patients with success, including a 95-year-old with itch refractory to other treatments (Yosipovitch, unpublished data). Adverse effects have not been specifically outlined in the elderly, but in the general adult population they include conjunctivitis, headache, and injection site reaction. There has been no demonstrated increased risk of secondary infections such as herpes viral infections or urinary tract infections that would be of particular concern when prescribing to the elder patient [ 112 ]. Several additional biologic therapies including targets of IL-31 and JAK show promise in early phase trials for their antipruritic properties particularly for AD, PN, and chronic idiopathic pruritus [ 113 , 114 ]. JAK inhibitors such as tofacitinib have adverse effects that should be strongly considered when used in the elderly including increased risk of herpes and other infections [ 115 ].

Neurokinin (NK1) Antagonists

NK1 is the receptor for substance P, and antagonist medications such as aprepitant and serlopitant have been shown to be effective in reducing itch of various etiologies, including malignancy, ESRD, idiopathic itch, and PN [ 115 , 116 ]. The relatively mild adverse effect profile of aprepitant has been demonstrated in several RCTs for use in other disease states such as depression and chemotherapy-induced nausea [ 117 ]. However, aprepitant is a known inducer of CYP3A4 and therefore has the potential for many drug–drug interactions [ 117 ].

Phototherapy

Ultraviolet A and B (UV-A and UV-B) phototherapy has been shown to improve pruritus in patients with AD, psoriasis, ESRD, and CTCL with limited evidence of its utility in PN [ 118 – 120 ]. In one retrospective study, Bulur et al. demonstrated elimination of pruritus in 80% of their elderly patients receiving narrowband UV-B treatment for chronic idiopathic pruritus [ 121 ]. Known risks of phototherapy include an erythematous sunburn reaction, aging of the skin, increased risk for non-melanoma skin cancer, and a paradoxical induction of itch if phototherapy doses are too high [ 122 ]. Despite concerns of potential adverse effects due to age-related barrier and immune function, the minimal dose to cause erythema has not been shown to differ significantly between older and younger populations and adverse effects are reported at comparable rates [ 123 , 124 ]. However, at least one study found that if erythema was elicited by phototherapy, the intensity was significantly increased in the elderly [ 124 ]. Consideration for low doses should be made for patients with high cumulative sun exposure or history of skin cancer. Also of note, some frequently used medications (i.e., antibiotics, NSAIDs, antihypertensives, and diuretics) can cause photosensitivity, and should not be used in conjunction with phototherapy.

Conclusions

Chronic itch is a common symptom in the elderly population and may be due to age-related changes in the skin, primary dermatologic conditions, systemic disease, neuropathic diseases, or medications. Determining the underlying cause of chronic itch is necessary for appropriate treatment. Because of medical co-morbidities, differential pharmacokinetics, polypharmacy, and potential for adverse reactions in the elderly, caution must be taken with certain medical therapies for chronic itch in this population.

Enhanced Digital Features

To view enhanced digital features for this article go to 10.6084/m9.figshare.9767126.

Acknowledgements

Funding

No funding or sponsorship was received for this study or publication of this article.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Gil Yosipovitch is Scientific Board Member of Menlo, Trevi, Sienna, Sanofi, Regeneron, Galderma, Pfizer, Novartis, Bayer, Kiniksa, Eli Lilly, Abbvie, Ortho, and Cervae and has received research support from Pfizer, Sun Pharma, Leo, Menlo, and Kiniksa. Kayla M. Fourzali has nothing to disclose.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

References

1. Thapa DP Jha AK Kharel C Shrestha S Dermatological problems in geriatric patients: a hospital based study Nepal Med Coll J 2012 14 3 193 195 24047013

2. Yalcin B Tamer E Toy GG Oztas P Hayran M Alli N The prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients Int J Dermatol 2006 45 6 672 676 10.1111/j.1365-4632.2005.02607.x 16796625

3. Weisshaar E Szepietowski JC Dalgard FJ European S2k guideline on chronic pruritus Acta Derm Venereol 2019 99 5 469 506 10.2340/00015555-3164 30931482

4. O’Donnell BF Lawlor F Simpson J Morgan M Greaves MW The impact of chronic urticaria on the quality of life Br J Dermatol 1997 136 2 197 201 10.1046/j.1365-2133.1997.d01-1168.x 9068731

5. Yosipovitch G Goon A Wee J Chan YH Goh CL The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis Br J Dermatol 2000 143 5 969 973 10.1046/j.1365-2133.2000.03829.x 11069504

6. Yosipovitch G Zucker I Boner G Gafter U Shapira Y David M A questionnaire for the assessment of pruritus: validation in uremic patients Acta Derm Venereol 2001 81 2 108 111 10.1080/00015550152384236 11501646

7. Kini SP DeLong LK Veledar E McKenzie-Brown AM Schaufele M Chen SC The impact of pruritus on quality of life: the skin equivalent of pain Arch Dermatol 2011 147 10 1153 1156 10.1001/archdermatol.2011.178 21680760

8. Valdes-Rodriguez R Mollanazar NK Gonzalez-Muro J Itch prevalence and characteristics in a Hispanic geriatric population: a comprehensive study using a standardized itch questionnaire Acta Derm Venereol 2015 95 4 417 421 10.2340/00015555-1968 25203328

9. Berger TG Shive M Harper GM Pruritus in the older patient: a clinical review JAMA 2013 310 22 2443 2450 10.1001/jama.2013.282023 24327039

10. Mollanazar NK Sethi M Rodriguez RV Retrospective analysis of data from an itch center: integrating validated tools in the electronic health record J Am Acad Dermatol 2016 75 4 842 844 10.1016/j.jaad.2016.05.035 27646746

11. Kim BS Berger TG Yosipovitch G Chronic pruritus of unknown origin (CPUO): uniform nomenclature and diagnosis as a pathway to standardized understanding and treatment J Am Acad Dermatol 2019 10.1016/j.jaad.2019.06.038 31238084

12. Paul C Maumus-Robert S Mazereeuw-Hautier J Guyen CN Saudez X Schmitt AM Prevalence and risk factors for xerosis in the elderly: a cross-sectional epidemiological study in primary care Dermatology 2011 223 3 260 265 10.1159/000334631 22104182

13. Ali SM Yosipovitch G Skin pH: from basic science to basic skin care Acta Derm Venereol 2013 93 3 261 267 10.2340/00015555-1531 23322028

14. Akiyama T Lerner EA Carstens E Protease-activated receptors and itch Handb Exp Pharmacol 2015 226 219 235 10.1007/978-3-662-44605-8_13 25861783 PMC5540334

15. Jensen JM Forl M Winoto-Morbach S Acid and neutral sphingomyelinase, ceramide synthase, and acid ceramidase activities in cutaneous aging Exp Dermatol 2005 14 8 609 618 10.1111/j.0906-6705.2005.00342.x 16026583

16. Luebberding S Krueger N Kerscher M Age-related changes in skin barrier function - quantitative evaluation of 150 female subjects Int J Cosmet Sci 2013 35 2 183 190 10.1111/ics.12024 23113564

17. Li J Tang H Hu X Chen M Xie H Aquaporin-3 gene and protein expression in sun-protected human skin decreases with skin ageing Australas J Dermatol 2010 51 2 106 112 10.1111/j.1440-0960.2010.00629.x 20546216

18. Ventura MT Casciaro M Gangemi S Buquicchio R Immunosenescence in aging: between immune cells depletion and cytokines up-regulation Clin Mol Allergy 2017 15 21 10.1186/s12948-017-0077-0 29259496 PMC5731094

19. Di Lorenzo G Di Bona D Belluzzo F Macchia L Immunological and non-immunological mechanisms of allergic diseases in the elderly: biological and clinical characteristics Immun Ageing 2017 14 23 10.1186/s12979-017-0105-4 29296117 PMC5738884

20. Lang P Mitchell W Lapenna A Pitts D Aspinall R Immunological pathogenesis of main age-related diseases and frailty: role of immunosenescence Eur Geriatr Med 2010 1 2 112 121 10.1016/j.eurger.2010.01.010

21. Colonna-Romano G Bulati M Aquino A B cell immunosenescence in the elderly and in centenarians Rejuvenation Res 2008 11 2 433 439 10.1089/rej.2008.0664 18442327

22. Haynes L Maue AC Effects of aging on T cell function Curr Opin Immunol 2009 21 4 414 417 10.1016/j.coi.2009.05.009 19500967 PMC3800142

23. Berger TG Steinhoff M Pruritus in elderly patients–eruptions of senescence Semin Cutan Med Surg 2011 30 2 113 117 10.1016/j.sder.2011.04.002 21767773 PMC3694596

24. Grewe M Chronological ageing and photoageing of dendritic cells Clin Exp Dermatol 2001 26 7 608 612 10.1046/j.1365-2230.2001.00898.x 11696065

25. Zegarska B Pietkun K Giemza-Kucharska P Zegarski T Nowacki MS Romanska-Gocka K Changes of Langerhans cells during skin ageing Postepy Dermatol Alergol 2017 34 3 260 267 10.5114/ada.2017.67849 28670257 PMC5471382

26. Goransson LG Mellgren SI Lindal S Omdal R The effect of age and gender on epidermal nerve fiber density Neurology 2004 62 5 774 777 10.1212/01.WNL.0000113732.41127.8F 15007129

27. Pogatzki-Zahn EM Pereira MP Cremer A Peripheral sensitization and loss of descending inhibition is a hallmark of chronic pruritus J Invest Dermatol 2019 10.1016/j.jid.2019.05.029 31276675

28. Comert A Akbas B Kilic EZ Psychiatric comorbidities and alexithymia in patients with seborrheic dermatitis: a questionnaire study in Turkey Am J Clin Dermatol 2013 14 4 335 342 10.1007/s40257-013-0019-7 23609607

29. Arsic Arsenijevic VS Milobratovic D Barac AM Vekic B Marinkovic J Kostic VS A laboratory-based study on patients with Parkinson’s disease and seborrheic dermatitis: the presence and density of Malassezia yeasts, their different species and enzymes production BMC Dermatol 2014 14 5 10.1186/1471-5945-14-5 24628775 PMC3995588

30. Ozkaya E Adult-onset atopic dermatitis J Am Acad Dermatol 2005 52 4 579 582 10.1016/j.jaad.2004.11.037 15793505

31. Aoyama H Tanaka M Hara M Tabata N Tagami H Nummular eczema: an addition of senile xerosis and unique cutaneous reactivities to environmental aeroallergens Dermatology 1999 199 2 135 139 10.1159/000018220 10559579

32. Farage MA Miller KW Berardesca E Maibach HI Clinical implications of aging skin: cutaneous disorders in the elderly Am J Clin Dermatol 2009 10 2 73 86 10.2165/00128071-200910020-00001 19222248

33. Schneider G Driesch G Heuft G Evers S Luger TA Stander S Psychosomatic cofactors and psychiatric comorbidity in patients with chronic itch Clin Exp Dermatol 2006 31 6 762 767 10.1111/j.1365-2230.2006.02211.x 17040260

34. Yosipovitch G Tang MB Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options Drugs Aging 2002 19 11 847 863 10.2165/00002512-200219110-00003 12428994

35. Henseler T Christophers E Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris J Am Acad Dermatol 1985 13 3 450 456 10.1016/S0190-9622(85)70188-0 4056119

36. Lo Schiavo A Ruocco E Brancaccio G Caccavale S Ruocco V Wolf R Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies Clin Dermatol 2013 31 4 391 399 10.1016/j.clindermatol.2013.01.006 23806156

37. Bastuji-Garin S Joly P Lemordant P Risk factors for bullous pemphigoid in the elderly: a prospective case-control study J Invest Dermatol 2011 131 3 637 643 10.1038/jid.2010.301 20944650

38. Hashimoto T Kursewicz CD Fayne RA Pathophysiological mechanisms of itch in bullous pemphigoid J Am Acad Dermatol 2019 10.1016/j.jaad.2019.07.060 31351883

39. Yosipovitch G Stander S Kerby MB Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial J Am Acad Dermatol 2018 78 5 882 10.1016/j.jaad.2018.02.030 29462657

40. Cassell JA Middleton J Nalabanda A Scabies outbreaks in ten care homes for elderly people: a prospective study of clinical features, epidemiology, and treatment outcomes Lancet Infect Dis 2018 18 8 894 902 10.1016/S1473-3099(18)30347-5 30068499 PMC6060176

41. Sanders KM Nattkemper LA Rosen JD Non-histaminergic itch mediators elevated in the skin of a porcine model of scabies and of human scabies patients J Invest Dermatol 2019 139 4 971 973 10.1016/j.jid.2018.09.032 30395848

42. Rosen JD Fostini AC Yosipovitch G Diagnosis and management of neuropathic itch Dermatol Clin 2018 36 3 213 224 10.1016/j.det.2018.02.005 29929594

43. Yamaoka H Sasaki H Yamasaki H Truncal pruritus of unknown origin may be a symptom of diabetic polyneuropathy Diabetes Care 2010 33 1 150 155 10.2337/dc09-0632 20040674 PMC2797961

44. Yawn BP Saddier P Wollan PC St Sauver JL Kurland MJ Sy LS A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction Mayo Clin Proc 2007 82 11 1341 1349 10.4065/82.11.1341 17976353

45. Goodkin R Wingard E Bernhard JD Brachioradial pruritus: cervical spine disease and neurogenic/neuropathic [corrected] pruritus J Am Acad Dermatol 2003 48 4 521 524 10.1067/mjd.2003.203 12664013

46. Marziniak M Phan NQ Raap U Brachioradial pruritus as a result of cervical spine pathology: the results of a magnetic resonance tomography study J Am Acad Dermatol 2011 65 4 756 762 10.1016/j.jaad.2010.07.036 21641675

47. Kwatra SG Stander S Bernhard JD Weisshaar E Yosipovitch G Brachioradial pruritus: a trigger for generalization of itch J Am Acad Dermatol 2013 68 5 870 873 10.1016/j.jaad.2012.11.026 23374230

48. Pisoni RL Wikstrom B Elder SJ Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS) Nephrol Dial Transplant 2006 21 12 3495 3505 10.1093/ndt/gfl461 16968725

49. Zucker I Yosipovitch G David M Gafter U Boner G Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease J Am Acad Dermatol 2003 49 5 842 846 10.1016/S0190-9622(03)02478-2 14576662

50. Hashimoto T, Yosipovitch G. Itching as a systemic disease. J Allergy Clin Immunol. 2019;144(2):375–380. 10.1016/j.jaci.2019.04.005 31004615

51. Dull MM Kremer AE Management of chronic hepatic itch Dermatol Clin 2018 36 3 293 300 10.1016/j.det.2018.02.008 29929600

52. Bergasa NV Carstens E Akiyama T Pruritus of cholestasis Itch: Mechanisms and treatment. Frontiers in neuroscience 2014 Boca Raton CRC

53. Heitkemper T Hofmann T Phan NQ Stander S Aquagenic pruritus: associated diseases and clinical pruritus characteristics J Dtsch Dermatol Ges. 2010 8 10 797 804 20546386 10.1111/j.1610-0387.2010.07463.x

54. Tefferi A Rumi E Finazzi G Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study Leukemia 2013 27 9 1874 1881 10.1038/leu.2013.163 23739289 PMC3768558

55. Hashimoto T Rosen JD Sanders KM Yosipovitch G Possible roles of basophils in chronic itch Exp Dermatol 2018 10.1111/exd.13705 29894005

56. Gobbi PG Attardo-Parrinello G Lattanzio G Rizzo SC Ascari E Severe pruritus should be a B-symptom in Hodgkin’s disease Cancer 1983 51 10 1934 1936 10.1002/1097-0142(19830515)51:10<1934::AID-CNCR2820511030>3.0.CO;2-R 6831358

57. Rowe B Yosipovitch G Paraneoplastic itch management Curr Probl Dermatol 2016 50 149 154 10.1159/000446060 27578084

58. Rubenstein M Duvic M Cutaneous manifestations of Hodgkin’s disease Int J Dermatol 2006 45 3 251 256 10.1111/j.1365-4632.2006.02675.x 16533224

59. Vij A Duvic M Prevalence and severity of pruritus in cutaneous T cell lymphoma Int J Dermatol 2012 51 8 930 934 10.1111/j.1365-4632.2011.05188.x 22788808

60. Mills KC Kwatra SG Feneran AN Itch and pain in nonmelanoma skin cancer: pain as an important feature of cutaneous squamous cell carcinoma Arch Dermatol 2012 148 12 1422 1423 10.1001/archdermatol.2012.3104 23247491 PMC3788599

61. Yosipovitch G Chronic pruritus: a paraneoplastic sign Dermatol Ther 2010 23 6 590 596 10.1111/j.1529-8019.2010.01366.x 21054705 PMC3150589

62. Skoog I Psychiatric disorders in the elderly Can J Psychiatry 2011 56 7 387 397 10.1177/070674371105600702 21835102

63. Lee HG Stull C Yosipovitch G Psychiatric disorders and pruritus Clin Dermatol 2017 35 3 273 280 10.1016/j.clindermatol.2017.01.008 28511824

64. Shevchenko A Valdes-Rodriguez R Yosipovitch G Causes, pathophysiology, and treatment of pruritus in the mature patient Clin Dermatol 2018 36 2 140 151 10.1016/j.clindermatol.2017.10.005 29566918

65. Fowler E Maderal A Yosipovitch G Treatment-induced delusions of infestation associated with increased brain dopamine levels Acta Derm Venereol 2019 99 3 327 328 10.2340/00015555-3093 30460371

66. Steckelings UM Artuc M Wollschlager T Wiehstutz S Henz BM Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions Acta Derm Venereol 2001 81 5 321 325 10.1080/000155501317140007 11800136

67. Reich A Stander S Szepietowski JC Drug-induced pruritus: a review Acta Derm Venereol 2009 89 3 236 244 10.2340/00015555-0650 19479118

68. Reich A Szepietowski JC Opioid-induced pruritus: an update Clin Exp Dermatol 2010 35 1 2 6 10.1111/j.1365-2230.2009.03463.x 19663845

69. Sibaud V Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy Am J Clin Dermatol 2018 19 3 345 361 10.1007/s40257-017-0336-3 29256113

70. Fischer A Rosen AC Ensslin CJ Wu S Lacouture ME Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4 Dermatol Ther 2013 26 2 135 148 10.1111/dth.12027 23551370

71. Kalaaji AN Wallo W A randomized controlled clinical study to evaluate the effectiveness of an active moisturizing lotion with colloidal oatmeal skin protectant versus its vehicle for the relief of xerosis J Drugs Dermatol 2014 13 10 1265 1268 25607563

72. Pazyar N Yaghoobi R Kazerouni A Feily A Oatmeal in dermatology: a brief review Indian J Dermatol Venereol Leprol 2012 78 2 142 145 10.4103/0378-6323.93629 22421643

73. Pan M Heinecke G Bernardo S Tsui C Levitt J Urea: a comprehensive review of the clinical literature Dermatol Online J 2013 19 11 20392 24314769

74. Young TA Patel TS Camacho F A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients J Dermatolog Treat 2009 20 2 76 81 10.1080/09546630802441218 18821119

75. Yosipovitch G Samuel LS Neuropathic and psychogenic itch Dermatol Ther 2008 21 1 32 41 10.1111/j.1529-8019.2008.00167.x 18318883

76. Andersen HH Arendt-Nielsen L Elberling J Topical capsaicin 8% for the treatment of neuropathic itch conditions Clin Exp Dermatol 2017 42 5 596 598 10.1111/ced.13114 28556308

77. Andersen HH Sand C Elberling J Considerable variability in the efficacy of 8% capsaicin topical patches in the treatment of chronic pruritus in 3 patients with notalgia paresthetica Ann Dermatol 2016 28 1 86 89 10.5021/ad.2016.28.1.86 26848223 PMC4737841

78. Laklouk M Baranidharan G Profile of the capsaicin 8% patch for the management of neuropathic pain associated with postherpetic neuralgia: safety, efficacy, and patient acceptability Patient Prefer Adher 2016 10 1913 1918 10.2147/PPA.S76506 PMC5038568 27703336

79. Zeidler C Luling H Dieckhofer A Capsaicin 8% cutaneous patch: a promising treatment for brachioradial pruritus? Br J Dermatol 2015 172 6 1669 1671 10.1111/bjd.13501 25354282

80. Lee HG Grossman SK Valdes-Rodriguez R Topical ketamine-amitriptyline-lidocaine for chronic pruritus: a retrospective study assessing efficacy and tolerability J Am Acad Dermatol 2017 76 4 760 761 10.1016/j.jaad.2016.10.030 28325395

81. Poterucha TJ Murphy SL Davis MD Topical amitriptyline-ketamine for the treatment of brachioradial pruritus JAMA Dermatol 2013 149 2 148 150 10.1001/2013.jamadermatol.646 23426470

82. Eichenfield LF Tom WL Berger TG Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies J Am Acad Dermatol 2014 71 1 116 132 10.1016/j.jaad.2014.03.023 24813302 PMC4326095

83. Gupta AK Versteeg SG Topical treatment of facial seborrheic dermatitis: a systematic review Am J Clin Dermatol 2017 18 2 193 213 10.1007/s40257-016-0232-2 27804089

84. Ropke MA Alonso C Jung S Effects of glucocorticoids on stratum corneum lipids and function in human skin-a detailed lipidomic analysis J Dermatol Sci 2017 88 3 330 338 10.1016/j.jdermsci.2017.08.009 28911799

85. Stander S Schurmeyer-Horst F Luger TA Weisshaar E Treatment of pruritic diseases with topical calcineurin inhibitors Ther Clin Risk Manag 2006 2 2 213 218 10.2147/tcrm.2006.2.2.213 18360595 PMC1661653

86. Gisondi P Ellis CN Girolomoni G Pimecrolimus in dermatology: atopic dermatitis and beyond Int J Clin Pract 2005 59 8 969 974 10.1111/j.1368-5031.2005.00587.x 16033622

87. Kailas A Crisaborole: a new and effective nonsteroidal topical drug for atopic dermatitis Dermatol Ther 2017 30 5 e12533 10.1111/dth.12533 28834023

88. Endo JO Wong JW Norman RA Chang ALS Geriatric dermatology: part I. Geriatric pharmacology for the dermatologist J Am Acad Dermatol 2013 68 4 521 10.1016/j.jaad.2012.10.063 23522421

89. Trevor A Katzung B Kruidering-Hall M Katzung and Trevor’s pharmacology examination and board review 2013 New York McGraw Hill

90. Hutchison L Sleeper R Asal N Fundamentals of geriatric pharmacotherapy: an evidenced-based approach 2015 Bethesda ASHP

91. American Geriatrics Society Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults J Am Geriatr Soc 2019 67 4 674 694 10.1111/jgs.15767 30693946

92. Gray SL Anderson ML Dublin S Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study JAMA Intern Med 2015 175 3 401 407 10.1001/jamainternmed.2014.7663 25621434 PMC4358759

93. Asero R Tedeschi A Cugno M Treatment of chronic urticaria Immunol Allergy Clin North Am 2014 34 1 105 116 10.1016/j.iac.2013.09.013 24262692

94. Stander S Bockenholt B Schurmeyer-Horst F Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study Acta Derm Venereol 2009 89 1 45 51 10.2340/00015555-0553 19197541

95. Mayo MJ Handem I Saldana S Jacobe H Getachew Y Rush AJ Sertraline as a first-line treatment for cholestatic pruritus Hepatology 2007 45 3 666 674 10.1002/hep.21553 17326161

96. Pongcharoen P Fleischer AB Jr An evidence-based review of systemic treatments for itch Eur J Pain 2016 20 1 24 31 10.1002/ejp.766 26416344

97. Torvinen-Kiiskinen S Tolppanen AM Koponen M Antidepressant use and risk of hip fractures among community-dwelling persons with and without Alzheimer’s disease Int J Geriatr Psychiatry 2017 32 12 e107 e115 10.1002/gps.4667 28055139

98. Hundley JL Yosipovitch G Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study J Am Acad Dermatol 2004 50 6 889 891 10.1016/j.jaad.2004.01.045 15153889

99. Potts GA Hurley MY Psoriasis in the geriatric population Clin Geriatr Med 2013 29 2 373 395 10.1016/j.cger.2013.01.004 23571034

100. Gupta MA Pur DR Vujcic B Gupta AK Use of antiepileptic mood stabilizers in dermatology Clin Dermatol 2018 36 6 756 764 10.1016/j.clindermatol.2018.08.005 30446200

101. Matsuda KM Sharma D Schonfeld AR Kwatra SG Gabapentin and pregabalin for the treatment of chronic pruritus J Am Acad Dermatol 2016 75 3 619 10.1016/j.jaad.2016.02.1237 27206757

102. Reszke R Szepietowski JC End-stage renal disease chronic itch and its management Dermatol Clin 2018 36 3 277 292 10.1016/j.det.2018.02.007 29929599

103. Ganesh A Maxwell LG Pathophysiology and management of opioid-induced pruritus Drugs 2007 67 16 2323 2333 10.2165/00003495-200767160-00003 17983254

104. Dawn AG Yosipovitch G Butorphanol for treatment of intractable pruritus J Am Acad Dermatol 2006 54 3 527 531 10.1016/j.jaad.2005.12.010 16488311

105. Phan NQ Bernhard JD Luger TA Stander S Antipruritic treatment with systemic mu-opioid receptor antagonists: a review J Am Acad Dermatol 2010 63 4 680 688 10.1016/j.jaad.2009.08.052 20462660

106. Fowler E Yosipovitch G Chronic itch management: therapies beyond those targeting the immune system Ann Allergy Asthma Immunol 2019 10.1016/j.anai.2019.01.016 30685562

107. Phan NQ Lotts T Antal A Bernhard JD Stander S Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review Acta Derm Venereol 2012 92 5 555 560 10.2340/00015555-1353 22504709

108. Cowan A Kehner GB Inan S Targeting itch with ligands selective for kappa opioid receptors Handb Exp Pharmacol 2015 226 291 314 10.1007/978-3-662-44605-8_16 25861786

109. Mathur VS Kumar J Crawford PW Hait H Sciascia T A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus Am J Nephrol 2017 46 6 450 458 10.1159/000484573 29253847

110. Simpson EL Akinlade B Ardeleanu M Two phase 3 trials of dupilumab versus placebo in atopic dermatitis N Engl J Med 2017 376 11 1090 1091 10.1056/NEJMc1700366 28296614

111. Blauvelt A de Bruin-Weller M Gooderham M Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial Lancet 2017 389 10086 2287 2303 10.1016/S0140-6736(17)31191-1 28478972

112. Ou Z Chen C Chen A Yang Y Zhou W Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis Int Immunopharmacol 2018 54 303 310 10.1016/j.intimp.2017.11.031 29182975

113. Erickson S Nahmias Z Rosman IS Kim BS Immunomodulating agents as antipruritics Dermatol Clin 2018 36 3 325 334 10.1016/j.det.2018.02.014 29929604

114. Oetjen LK Mack MR Feng J Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch Cell 2017 171 1 217 10.1016/j.cell.2017.08.006 28890086 PMC5658016

115. McEwen MW Fite EM Yosipovitch G Patel T Drugs on the horizon for chronic pruritus Dermatol Clin 2018 36 3 335 344 10.1016/j.det.2018.02.016 29929605

116. Stander S Kwon P Hirman J Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial J Am Acad Dermatol 2019 80 5 1395 1402 10.1016/j.jaad.2019.01.052 30894279

117. He A Alhariri JM Sweren RJ Kwatra MM Kwatra SG Aprepitant for the treatment of chronic refractory pruritus Biomed Res Int 2017 2017 4790810 10.1155/2017/4790810 29057261 PMC5625747

118. Rivard J Lim HW Ultraviolet phototherapy for pruritus Dermatol Ther 2005 18 4 344 354 10.1111/j.1529-8019.2005.00032.x 16297008

119. Nakamura M Koo JY Phototherapy for the treatment of prurigo nodularis: a review Dermatol Online J 2016 22 13030 27617458

120. Baldo A Sammarco E Plaitano R Martinelli V Monfrecola G Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera Br J Dermatol 2002 147 5 979 981 10.1046/j.1365-2133.2002.04983.x 12410710

121. Bulur I Erdogan HK Aksu AE Karapinar T Saracoglu ZN The efficacy and safety of phototherapy in geriatric patients: a retrospective study An Bras Dermatol 2018 93 1 33 38 10.1590/abd1806-4841.20185468 29641694 PMC5871359

122. Legat FJ Is there still a role for UV therapy in itch treatment? Exp Dermatol 2019 10.1111/exd.14011 31343082

123. Powell JB Gach JE Phototherapy in the elderly Clin Exp Dermatol 2015 40 6 605 610 10.1111/ced.12626 25809797

124. Gloor M Scherotzke A Age dependence of ultraviolet light-induced erythema following narrow-band UVB exposure Photodermatol Photoimmunol Photomed 2002 18 3 121 126 10.1034/j.1600-0781.2002.00756.x 12207674